Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

@article{Maini1999InfliximabA,
  title={Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial},
  author={R. Maini and E. Clair and F. Breedveld and D. Furst and for the Attract Study Group},
  journal={The Lancet},
  year={1999},
  volume={354},
  pages={1932-1939}
}
  • R. Maini, E. Clair, +2 authors for the Attract Study Group
  • Published 1999
  • Medicine
  • The Lancet
    • BACKGROUND Not all patients with rheumatoid arthritis can tolerate or respond to methotrexate, a standard treatment for this disease. There is evidence that antitumour necrosis factor alpha (TNFalpha) is efficacious in relief of signs and symptoms. We therefore investigated whether infliximab, a chimeric human-mouse anti-TNFalpha monoclonal antibody would provide additional clinical benefit to patients who had active rheumatoid arthritis despite receiving methotrexate. METHODS In an… CONTINUE READING
    View on Elsevier
    doi.org
    2,355 Citations
    Highly Influencial Citations
    75
    Background Citations
    426
    Methods Citations
    48
    Results Citations
    49
    2,355 Citations
    Citation Type

    Citation Type

    Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
    • 2,993
    • PDF
    Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
    • 261
    • PDF
    Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
    • 479
    Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.
    • 1,129
    • PDF
    Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit.
    • 62
    • PDF
    Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study.
    • 173
    • PDF
    Efficacy and safety of the fully human anti-tumour necrosis factor a monoclonal antibody adalimumab ( D 2 E 7 ) in DMARD refractory patients with rheumatoid arthritis : a 12 week , phase II study
    • 3
    • PDF
    Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab bef
    • 382
    Long term safety of infliximab.
    • T. Schaible
    • Medicine
    • Canadian journal of gastroenterology = Journal canadien de gastroenterologie
    • 2000
    • 109
    • PDF
    Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials.
    • 49

    References

    SHOWING 1-10 OF 22 REFERENCES
    Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis
    • 1,708
    Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
    • 1,648
    A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.
    • 2,077
    Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.
    • 870
    Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group.
    • 483
    Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.
    • 1,589
    Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis
    • 656
    The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis.
    • 230
    • PDF
    Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.
    • 648
    Monoclonal anti‐TNFα Antibody as a Probe of Pathogenesis and Therapy of Rheumatoid Disease
    • 186